



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

EDITORIAL

Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19



SCOTT W. MCPHERSON, JAN E. KEUNEN, ALAN C. BIRD, EMILY Y. CHEW, AND FREDERIK J. VAN KUIJK

THE NOVEL CORONAVIRUS DISEASE OF 2019 (COVID-19), which can cause a severe respiratory syndrome in humans, results from infection by the SARS-CoV-2 virus. A very recent report identified the interaction between the receptor-binding domain of the spike glycoprotein (S protein) of SARS-CoV-2 and the peptidase domain of angiotensin-converting enzyme 2 (ACE2) as critical for viral entry into host cells.¹ Because of the strong link between ACE2 and SARS-CoV-2 infection, inhibitors of ACE2 have been discussed as potential therapeutic agents against COVID-19.^{2,3} We believe there already might be a safe, potential inhibitor of ACE2 function that could constrain the ability of SARS-CoV-2 to infect cells—and that is the trace mineral zinc. Given that zinc supplements are widely used, proven safe in moderate doses, and available without prescription, we propose that there is an urgent need to determine if zinc can be an effective prophylactic treatment against COVID-19.

SARS-CoV-2 is an enveloped, positive strand RNA virus that is about 80% identical to the SARS-CoV virus that was responsible for the severe acute respiratory syndrome (SARS) outbreak of 2002-2003. Research at that time identified interaction between the S protein of SARS-CoV and ACE2 as a mechanism of viral infection.⁴ ACE2 is a type I integral membrane protein characterized by the HEXXH + E zinc-binding domain and is found on the surface of epithelial cells of the heart, lung, kidney, and intestine. ACE2 has also been found to be expressed in cells of the upper respiratory tract and in oral epithelial cells.^{5,6} This could explain why the SARS-CoV-2 virus can be highly infectious and COVID-19 symptoms can include pneumonia and diarrhea. Despite being a zinc metallopeptidase, very little research has been done on the effect of exogenous zinc on ACE2 function. One report showed

that zinc blocked the ability of ACE2 to metabolize substrate in a dose-dependent manner starting at concentrations as small as 10 μM ,⁷ indicating that zinc could possibly inhibit the interaction between SARS-CoV-2 S protein and ACE2.

Although limited, there are research findings concerning the antiviral effects of zinc.⁸ It was first shown that zinc lozenges, which coat the oral cavity with zinc, were somewhat effective with short-term use at mitigating the duration of rhinovirus infections especially at doses greater than 75 mg zinc daily.^{9,10} It has also been suggested zinc can limit influenza virus infections.^{11,12} The antiviral effects of zinc against rhinoviruses and influenza are thought to be due to enhanced immune cell function,^{8,11,12} although the ability of zinc to interfere with the binding of these viruses to cells remains a possibility. It has also been suggested that zinc can inhibit coronavirus replication by the inhibition of RNA synthesis.¹³ Clearly, there is an urgent need to further study the antiviral mechanisms of zinc, particularly as they relate to coronaviruses. It should be noted that SARS-CoV-2, influenza, and rhinoviruses all use different cellular receptors, but the presence of ACE2 on the epithelium of the oral cavity and upper airway offers an excellent rationale for oral zinc therapy.

Based on the Age-Related Eye Disease Study (AREDS) and the AREDS 2 studies¹⁴ many, primarily elderly, are already taking zinc-containing supplements in order to limit the progression of their age-related macular degeneration. Normal serum levels of zinc are around 12 μM , and the AREDS formula, which provides 80 mg of zinc daily, was able to increase serum zinc by 17% within 1 year.¹⁵ It should be studied to determine if this increase in zinc can prevent or limit disease duration for those particularly vulnerable to COVID-19.

We realize the scientific and clinical evidence to fully support the use of an oral zinc supplement as a prophylactic agent remains incomplete. Given that a vaccine is at least a year away, any safe, natural compound with antiviral potential should be given serious consideration as a prophylactic agent. Double-blind, placebo-controlled studies will ultimately need to be done to prove the efficacy of zinc supplements against SARS-CoV-2. However, because of their availability, safety, and potential benefits, they merit strong consideration for immediate studies (analyzing

Accepted for publication Apr 20, 2020.

From the Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA (S.W.M., F.J.v.K.); Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands (J.E.K.); Moorfields Eye Hospital, London, United Kingdom (A.C.B.); and Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA (E.Y.C.).

Inquiries to Frederik J. van Kuijk, Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN 55455, USA; e-mail: vankuijk@umn.edu

possible differences in progression of respiratory disease patients between AREDS 2 users and abstainers) by health researchers at this time to identify a possible tool that can work against COVID-19. In view of the serious, life-threatening circumstances of this pandemic, we believe there is potential benefit in taking oral zinc for those at risk of developing COVID-19. Therefore, shorter open-label retrospective studies should be quickly completed.

Whether or not any benefit from oral zinc can be demonstrated, we warn users strongly against taking more zinc

than provided by the AREDS 2 formula and developing a false sense of security by using oral zinc. Social distancing and meticulous hand hygiene remain of the utmost importance in limiting the spread of COVID-19 and should continue to be the primary strategy against the SARS-CoV-2 pandemic.

In summary, investigating oral zinc supplementation for the prevention of COVID-19 should commence immediately.

FUNDING/SUPPORT: S.W.M. AND F.J.V.K. ARE SUPPORTED BY THE MINNESOTA LIONS VISION FOUNDATION. FINANCIAL DISCLOSURES: None. All authors attest that they meet the current ICMJE criteria for authorship.

In memory of our Chinese colleague Li Wenliang, MD (1986-2020).

REFERENCES

1. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* 2020;367(6485):1444–1448.
2. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med* 2020;46(4):586–590.
3. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV2 cell entry depends on ACE2 and TMPRSS2 and is blocked by clinically proven protease inhibitor. *Cell* 2020;181(2):271–280.
4. Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. *Virology* 2001;279(2):371–374.
5. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infections depend on differentiation of human airway epithelia. *J Virol* 2005;79(23):14614–14621.
6. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020;12(8).
7. Speth R, Carrera E, Jean-Baptiste M, Joachim A, Linares A. The concentration-dependent effects of zinc on angiotensin-converting enzyme 2 activity. *FASEB J* 2014;28(1_supplement).
8. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The role of zinc in antiviral immunity. *Adv Nutr* 2019;10(4):696–710.
9. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc-gluconate lozenges for treating the common cold. *Ann Intern Med* 1996;125(2):81–88.
10. Helima H. Zinc lozenges may shorten the duration of colds: a systematic review. *Open Respir Med J* 2011;5:51–58.
11. Sandstead HH, Prasad AS. Zinc Intake and resistance to H1N1 influenza. *Am J Public Health* 2010;100(6):970–971.
12. Ghaffari H, Tavakoli A, Moradi A, et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. *J Biomed Sci* 2019;26(1):70.
13. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn²⁺ inhibits coronavirus and arterivirus RNA polymerase activity in-vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010;6(11):e1001176.
14. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA* 2013;309(19):2005–2015.
15. Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol, and hematocrit in persons randomly assigned to treatment group in the Age-Related Eye Disease Study: AREDS report no. 7. *J Nutr* 2002;132(4):697–702.